Zak Doric, PhD, is an Investment Partner at Andreessen Horowitz on the Bio + Health team, focused on biotechnology investments spanning seed to Series A stages. He invests in AI-driven drug discovery, computational biology, and life sciences tools.

Zak earned his PhD from UCSF and Gladstone Institutes, researching Parkinson's disease and mitochondrial biology in neurodegenerative disorders. He completed a fellowship at Flagship Pioneering and consulted at Bain & Company before joining a16z in 2022.

Zak co-authored research published in Nature Communications on mitochondrial recycling pathways linked to Parkinson's disease. He holds expertise in neuroscience, biotech investing, and AI applications in life sciences.

At a16z, Zak co-led Phylo's $13.5M seed round and authored thought leadership on AI's role in biotech innovation. His investment range spans $500K to $40M with a focus on early-stage biotechnology companies.

Zak's portfolio work supports companies developing AI scientists and computational tools used by thousands of labs globally. He contributes to a16z's $2.2B Bio + Health fund, advancing the intersection of AI and drug development.